Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$65.68 USD

65.68
3,456,884

-1.42 (-2.12%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (59 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance.

Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure

by Zacks Equity Research

Bio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Charles River (CRL) to Advance AI Drug Discovery With New Pact

by Zacks Equity Research

Charles River's (CRL) recent partnership will enable the optimization of the discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.

Here's Why Investors Should Buy Alcon (ALC) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about Alcon (ALC), backed by a competitive product portfolio and strong commercial execution.

Henry Schein (HSIC) Q3 Revenues Miss, 2023 Guidance Cut

by Zacks Equity Research

Henry Schein's (HSIC) third-quarter 2023 performance demonstrates remarkable sales growth in the Technology and Value-Added Service businesses.

Humana's (HUM) CenterWell Unit Plans Expansion in Indiana

by Zacks Equity Research

Humana's (HUM) CenterWell brand will open four senior-focused primary care centers across Indianapolis in order to address the unique needs of the area's senior population.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health's (CVS) strength in Health Care Benefits business arm and stable solvency position.

Quest Diagnostics (DGX) Introduces Mobile Phlebotomy Service

by Zacks Equity Research

Quest Diagnostics (DGX) can offer patients and physicians a seamless connection to Quest Diagnostic's laboratory testing with the launch of Quest Mobile.

IDEXX's (IDXX) Upcoming Launch to Detect Canine Leishmaniosis

by Zacks Equity Research

IDEXX (IDXX) expands the SNAP franchise with a comprehensive solution for detecting canine leishmaniosis.

Hologic's (HOLX) Q4 Earnings Beat Estimates, Gross Margin Down

by Zacks Equity Research

Solid year-over-year growth in the Breast Health segment drives Hologic's (HOLX) Q4 performance.

National Vision (EYE) Q3 Earnings Top Estimates, Margins Fall

by Zacks Equity Research

National Vision's (EYE) higher SG&A expenses in the third quarter reflect increases in performance-based incentives and stock-based compensations.

Illumina (ILMN) Q3 Earnings Surpass Estimates, '23 View Cut

by Zacks Equity Research

Illumina (ILMN) reports solid earnings in the third quarter of 2023 amid a challenging macro environment.

BD (BDX) Q4 Earnings In-Line With Estimates, Margins Contract

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in all its segments and both geographic regions in the fiscal fourth quarter.

Surmodics (SRDX) Q4 Earnings Top Estimates, Revenues Up Y/Y

by Zacks Equity Research

Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust segmental revenues.

Inspire Medical (INSP) Q3 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the third quarter.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business and momentum in ProCyte One expansion.

Phibro (PAHC) Q1 Earnings and Revenues Miss, Margins Down

by Zacks Equity Research

Phibro's (PAHC) fiscal 2024 first-quarter performance reflects reduced sales in Mineral Nutrition and Performance Products.

Inogen (INGN) Q3 Earnings Miss Estimates, Revenues Down Y/Y

by Zacks Equity Research

Despite higher international business-to-business sales and rental revenues, Inogen's (INGN) overall third-quarter results reflect soft performances.

Accuray (ARAY) Q1 Earnings In-Line With Estimates, Revenues Top

by Zacks Equity Research

Accuray (ARAY) reports a solid fiscal first quarter top line on the back of robust Product revenues.

DaVita (DVA) Q3 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

DaVita's (DVA) robust segmental revenues drive its third-quarter performance.

Chemed's (CHE) VITAS Performance Aids, Macro Issues Linger

by Zacks Equity Research

Chemed (CHE) believes Roto-Rooter is well-positioned for growth and anticipates continued expansion of the segment's market share.

Masimo (MASI) Q3 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

Masimo's (MASI) overall third-quarter results reflect soft performance despite strength in the Hearables category.

STERIS (STE) Q2 Revenues Surpass Estimates, Margins Down

by Zacks Equity Research

STERIS' (STE) fiscal 2024 second-quarter results reflect continued momentum in the Healthcare business.

OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall third-quarter results reflect soft performances.